Pfizer close to acquiring Metsera for $7.3B, targeting breakthrough obesity drug

Pfizer is making a bold move in the pharmaceutical world by closing in on a $7.3 billion deal to acquire Metsera, a biotech firm focused on next-generation anti-obesity drugs, news platform Financial Times reported on Monday.

This acquisition underlines Pfizer’s fresh push into the booming weight-loss drug market, an area showing rapid growth as obesity rates climb worldwide.

After facing challenges with its own weight loss drug programs, Pfizer sees this as a strategic way to strengthen its portfolio and join the race against established leaders in obesity treatments.

Pfizer eyes Metsera obesity breakthrough

The deal offers Metsera shareholders $47.50 per share in cash, with an additional $22.50 per share payable if certain performance targets are hit.

This premium of about 42% over Metsera’s recent share price reflects Pfizer’s eagerness to secure the promising biotech.

Metsera, based in New York and founded in 2022, has been developing innovative obesity treatments primarily through GLP-1 receptor agonists.

Its standout drug candidate, MET-097i, is designed to be injected once a month and has shown an average weight loss of 11.3% in mid-stage clinical trials, a major convenience leap compared to the weekly injections offered by Pfizer’s competitors.

Pfizer’s acquisition would be a sharp turnaround after it halted its own oral GLP-1 drug development earlier this year due to safety issues.

The deal, expected to be announced soon pending final talks, gives Pfizer access to Metsera’s pipeline, which includes potential combination therapies, positioning the company well in the obesity treatment space.

This payment structure, blending cash upfront with milestone incentives, aligns costs with drug development success, lowering some risk for Pfizer while aiming for high rewards.

Obesity drug race heats up

Pfizer’s move is a clear sign of how hot the obesity drug market has become, dominated until now by giants like Novo Nordisk and Eli Lilly.

These firms have scored major wins with GLP-1 therapies enabling significant weight loss, but Pfizer sees an opportunity with Metsera’s once-monthly dosing, which could attract patients looking for easier treatment options and improve drug adherence.

This deal highlights the trend of big pharma companies aggressively buying into promising biotech startups to keep pace with innovation rather than relying solely on internal development.

The acquisition also raises the stakes, as the anti-obesity market is forecasted to explode to nearly $100 billion by 2030, driven by demand for more effective, patient-friendly treatments.

While milestone-based payments introduce risk if Metsera’s drugs fall short in trials, Pfizer’s bet signals confidence in this expanding field.

The acquisition is poised to intensify competition and could spark more deals and technological advances, as companies race to capture a share of the lucrative, fast-evolving obesity drug market.

Ultimately, Pfizer’s bold purchase aims to place it among the leaders challenging the current duopoly and addressing a critical global health issue.